Clinical Utility of Adjunctive High-Risk Human Papillomavirus DNA Testing in Women With Papanicolaou Test Findings of Atypical Glandular Cells
|
|
- Chloe Fox
- 5 years ago
- Views:
Transcription
1 Clinical Utility of Adjunctive High-Risk Human Papillomavirus DNA Testing in Women With Papanicolaou Test Findings of Atypical Glandular Cells Chengquan Zhao, MD; Anca Florea, MD; R. Marshall Austin, MD, PhD N Context. Atypical glandular cell (AGC) Papanicolaou (Pap) test interpretations are challenging. Most biopsy findings are benign, but AGC results may also reflect highly significant noninvasive neoplastic and malignant histologic outcomes. High-risk human papillomavirus (hrhpv) test use with AGC Pap test results is evolving. Objective. To further evaluate the utility and limitations of hrhpv testing with AGC Pap tests. Design. Hospital records were searched for AGC Pap tests results from June 1, 2005, to August 31, Cases of AGC with hrhpv tests and histopathologic follow-up were included. Results. Of the 662 women with AGC Pap test results and follow-up analyzed, hrhpv results were available for 309 (46.7%) and were positive in 75 cases (24.3%). Among the 75 cases with hr AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrhpv 2 results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma. Conclusions. Positive hrhpv AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years. Positive hrhpv AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years. Of note, hrhpv 2 AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s. Testing for hrhpv after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years. (Arch Pathol Lab Med. 2010;134: ) Accepted for publication April 10, From the Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. The authors have no relevant financial interest in the products or companies described in this article. Presented in part at the annual meeting of the United States and Canadian Academy of Pathology, Denver, Colorado, March 1 7, Reprints: Chengquan Zhao, MD, Department of Pathology, Magee- Womens Hospital of University of Pittsburgh Medical Center, 300 Halket St, Pittsburgh, PA ( zhaoc@upmc.edu). Atypical glandular cell (AGC) interpretations 1 2 and screening for glandular cervical neoplasia 3 7 remain some of the major challenges in gynecologic cytopathology. Even though most Papanicolaou (Pap) tests with AGC findings turn out to reflect a variety of underlying benign conditions, 8 10 a significant subset of AGC cases reflect underlying cervical intraepithelial neoplasia (CIN) grades 2/3 and/or endocervical adenocarcinoma in situ (AIS) as well as occasional cases of invasive cervical and noncervical carcinoma Cervical glandular cancers remain a major challenge to cervical cancer prevention efforts in the United States because cervical glandular cancers continue to increase even as squamous carcinomas have experienced an accelerated decline since the advent of liquid-based cytology. 21,22 The low incidence of AGC Pap test results 23 to date has limited our understanding of how best to integrate highrisk human papillomavirus (hrhpv) testing into AGC follow-up algorithms. Nevertheless, several series examining possible roles for hrhpv testing in patients with AGC Pap test results are accumulating Accordingly, we sought to analyze our histologic follow-up results for women with AGC Pap test findings and available hrhpv test results in a large, integrated, academic health system that was a participant in the atypical squamous cells of undetermined significance (ASC-US)/low-grade squamous intraepithelial lesion triage study 38 and an early adopter of widespread adjunctive hrhpv testing. MATERIALS AND METHODS Case Selection A retrospective study was approved by the institutional review board at the University of Pittsburgh Medical Center (Pittsburgh, Pennsylvania). The computerized records at Magee-Womens Hospital, University of Pittsburgh Medical Center, from June 1, 2005, to August 31, 2007, were searched for cases with AGC cytology. The final diagnoses of AGC were made by staff cytopathologists, based on categories defined by the 2001 Bethesda System 39 : AGC, either endocervical (AGC- EC), endometrial (AGC-EM), glandular cells not otherwise specified (AGC-NOS), and AGC favor neoplasia, either endocervical (AGC-EC-FN) or not otherwise specified (AGC- NOS-FN). Cases with cytologic interpretations of endocervical AIS and adenocarcinoma were not included in this study. Arch Pathol Lab Med Vol 134, January 2010 HPV Testing in AGC Pap Zhao et al 103
2 Table 1. Correlation of the Atypical Glandular Cell (AGC) Subcategories for 309 Cases With High-Risk Human Papillomavirus (hrhpv) DNA Testing and Histologic Diagnoses of Neoplastic or Malignant Lesions on Surgical Pathology Follow-up AGC/ASC-US (n = 97), AGC/ASC-H (n = 29), AGC/HSIL (n = 4), Cytologic Result HPV HPV HPV Age, y (range) 45.1 (19 84) 41.5 (21 76) 34.4 (24 45) Histologic diagnosis, % Squamous cell CIN 10 (58.8) 10 (12.5) 4 (33.3) 5 (29.4) 3 (100) 1 (100) CIN 2/3, No. 3 a 2 a 2 a 1 CIN 1, No Glandular cell cervical neoplasia 1 (5.9) 0 2 (16.7) 1 (5.9) 1 (33.3) 0 Invasive cervical carcinoma, No. 1 c AIS, No. 1 a 2 a 1 a Endometrial neoplasia 0 6 (7.5) Endometrial carcinoma 3 Endometrial hyperplasia 3 Ovarian neoplasia Serous carcinoma Abbreviations: AGC-EC, AGC-endocervical; AGC-EM, AGC-endometrial cells; AGC-NOS, AGC, not otherwise specified; AIS, adenocarcinoma in situ; ASC-H, atypical squamous cells, cannot exclude high-grade squamous lesion; ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia (grades 1 and 2/3); HSIL, high-grade squamous intraepithelial lesion. a One case with CIN 2, CIN 3, and AIS; 4 cases with both CIN 2/3 and AIS. b Including 7 cases of endometrioid cancer and 1 case of papillary carcinoma. c Adenosquamous carcinoma (older patient, HPV 2 ). Some women with AGC Pap tests had coexisting squamous abnormalities, such as ASC-US; atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); and high-grade squamous intraepithelial lesion (HSIL). These subsets of cases were separated from other cases with AGC and no coexisting squamous cell abnormalities. Papanicolaou tests with findings of AGC and coexisting squamous abnormalities were included in the study as well-defined AGC subsets: AGC and ASC-US, AGC and ASC-H, AGC and HSIL. For the purposes of this study, all AGC cases were divided into 1 of the 6 following diagnostic categories: AGC and ASC-US, AGC and ASC-H, AGC and HSIL, AGC-EC, AGC-EM, and AGC-NOS. Intentionally, AGC favor neoplasia is a rarely used designation at this facility. Available literature and extensive personal experience in Pap-related litigation and other retrospective reviews indicate that this AGC subtype is poorly reproducible. We prefer to emphasize to clinicians that all AGC subtypes reflect significant risk for underlying consequential disease and the need for recommended, but often neglected, initial follow-up tissue examinations. Surgical Pathology Follow-up Follow-up included review and recording of surgical pathology results, including cervical biopsies, endocervical curettages, cone excisions, loop electrosurgical excision procedures, endometrial biopsies and curettages, and hysterectomies. For patients undergoing 2 or more procedures during the follow-up period, only the histologic diagnosis most out of reference range was recorded. Findings of abnormal histopathologic lesions were categorized into 4 large groups: (1) cervical squamous lesions, including (CIN 1) and CIN 2/3; (2) cervical glandular lesions, including AIS and invasive adenocarcinoma; (3) endometrial lesions, including endometrial hyperplasia, complex atypical hyperplasia (CAH), and endometrial carcinoma; and (4) metastatic malignancy. In this article, CIN terminology is used exclusively for histologic diagnoses. Low-grade squamous intraepithelial lesion and HSIL terminology refers exclusively to cytologic results. Benign lesions, including endometrial polyps, endometritis, endocervical polyps, endocervical tubal metaplasia, and endocervical microglandular hyperplasia, were recorded. Each patient s age at time of AGC diagnosis, time elapsed from Pap test until colposcopic examination and cervical biopsy, follow-up procedures, and histologic findings were abstracted from the records. Papanicolaou Test Methods Papanicolaou tests specimens were collected by a highly diverse group of clinical providers, which included gynecologists, family physicians, internists, nurse practitioners, physician assistants, and trainees. All cytology specimens were processed and evaluated in the large, academic cytopathology laboratory at Magee-Womens Hospital and reported using current 2001 Bethesda System terminology. The Magee-Womens Hospital/ University of Pittsburgh Medical Center cytopathology laboratory is a large, subspecialized, academic hospital laboratory, which consistently reports more than Pap tests per year from a large integrated hospital health system and which serves a metropolitan area with a significantly older age profile than the national average. 47 Approximately 98% of Pap tests in this hospital are ThinPrep Pap tests prepared according to manufacturer s specifications from PreservCyt samples using an automated processor (ThinPrep 3000; Cytyc Corporation, Marlborough, Massachusetts). Staining of slides was done on a Sakura Tissue Tek Automated Slide Stainer (Cytyc) according to a US Food and Drug Administration approved manufacturer s protocol. Location-guided, computer-assisted screening of ThinPrep Pap tests slides was accomplished using the ThinPrep Imaging System (Cytyc). 48 The cytology laboratory at Magee-Womens Hospital employs conservative workload policies (mean 8.0; range, Pap tests per cytotechnologist screening hour) and has a continuous, quality improvement program that focuses on staff education through multiple slide-blinded reviews of abnormal and questionably abnormal, internal and external consultation, Pap test results that precede later tissue-documented cases of CIN 2/3, AIS, cervical carcinoma, and noncervical uterine carcinoma. Human Papillomavirus Testing Testing for hrhpv DNA was ordered by clinicians according to several ordering options: reflex testing, triggered by indeterminate abnormal atypical squamous cell Pap test results; routine cotesting with Pap testing in women 30 years and older; and hrhpv DNA cotesting, regardless of age or Pap test result. Detection of hrhpv DNA was performed using the commercially available US Food and Drug Administration approved Hybrid Capture 2 system 49 (Digene Corporation, Gaithersburg, Maryland). 104 Arch Pathol Lab Med Vol 134, January 2010 HPV Testing in AGC Pap Zhao et al
3 Table 1. Extended AGC-EM (n = 19), AGC-EC (n = 75), AGC-NOS (n = 85), Total (n = 309), HPV HPV HPV HPV 52.2 (42 77) 38.7 (19 72) 46.3 (27 84) 43.9 (19 84) (5.6) 15 (53.6) 12 (25.5) 7 (50.0) 3 (4.2) 39 (52.0) 32 (13.7) 4 a (25.0) 0 2 (14.3) 0 13 (17.3) 1 (0.4) a (22.2) 0 1 (2.1) 0 4 (5.6) 0 15 (6.4) b (2.1) (0.4) 1 1 Statistical Analysis Statistical analysis included a x 2 test and a Fisher exact test for small numbers using the SAS software system, Version 9.1 (SAS Inc, Cary, North Carolina). P,.05 was considered statistically significant. RESULTS AGC Subcategories and Histopathologic Outcomes During the June 1, 2005, to August 31, 2007, 27-month study period, Pap tests were reported. The number of AGC results reported in this period was 1021 (0.41%). Test results for hrhpv from residual-vial fluid were available in 309 of 662 cases (46.7%) of AGC that also had available tissue follow-up results. The 309 cases of AGC were subclassified as AGC and ASC-US (n 5 97; 31.4%), AGC and ASC-H (n 5 29; 9.4%), AGC and HSIL (n 5 4; 1.3%), AGC-EM (n 5 19; 6.1%), AGC-EC (n 5 75; 24.3%), and AGC-NOS (n 5 85; 27.5%). The ages of women who had AGC ThinPrep Pap and reflex Hybrid Capture 2 hrhpv DNA test results ranged from 19 to 84 years, with a mean age of 44 years. The ages in different groups are listed in Table 1. The mean histologic followup period was 2.7 months, with a range of 10 days to 22 months. Of the 309 cases of AGC, 97 women (31.4%) had neoplastic histologic follow-up results, including 71 cases with CIN (23.0%); 14 cases with cervical glandular neoplasia (4.5%), which included 4 cases with both AIS and CIN 2/3; 15 cases with endometrial neoplasias (4.9%), and 1 case with metastatic ovarian carcinoma (1%). The incidence of CIN was significantly higher than that of cervical glandular neoplastic lesions and endometrial neoplasias (both P,.001). The incidences of cervical glandular and endometrial neoplasias showed no statistical difference (P 5.85). A positive hrhpv DNA result was obtained in 75 of the 309 women (24.3%) with AGC Pap test results and available histologic follow-up. The hr rates were highest in women with AGC and HSIL (75.0%), AGC and ASC-H (41.4%), and AGC-EC (37.3%) and were lowest in the AGC-EM group (5.3%). Women with AGC results had a higher risk for detection of CIN (52.0%) and glandular neoplasia (17.3%) than women with HPV 2 AGC results (13.7% for CIN and 0.4% for endocervical glandular lesions). The differences were statistically significant (P,.001). When the histologic results were analyzed with respect to the initial Pap test interpretive subgroups and the hrhpv test results, an interpretation of AGC-EM was most often (22.2%) associated with a significant endometrial lesion and a negative HPV result. Negative hrhpv DNA results were present in all women with AGC Pap tests who, on histologic follow-up, had endometrial hyperplasia or endometrial cancer. Of the neoplastic lesions in the AGC-EM follow-up group, 80.0% (4 of 5) were endometrial in origin. In both AGC-EC and AGC-NOS groups, the incidence of CIN was higher than for cervical glandular lesions (AGC-EC, 27 versus 7; AGC- NOS, 10 versus 2). Of the hr AGC-EC and AGC-NOS cases, 25.0% and 14.3%, respectively, had cervical glandular lesions. One HPV 2, AGC 2, ASC-H case had followup findings of an endocervical adenosquamous carcinoma, but no cases of AGC-EC or AGC-NOS with negative hrhpv showed cervical glandular neoplasia. In the summarized initial group of Pap test results with AGC and abnormal squamous cells, CIN was found in 52.0% and 13.7% of women who were hr and hrhpv 2, respectively (P,.001). Cervical intraepithelial neoplasia associated with an HPV 2 AGC result was CIN 1 in 31 of 32 cases (96.9%). Histologic cervical glandular neoplasias were found in 17.3% and 0.4% of women who were hr and hrhpv 2, respectively (P,.001). Table 1 summarizes the follow-up test with abnormal histologic results based on the initial Pap test subgroups and hrhpv test results in details. Age and Histopathologic Outcomes When age, hrhpv test results, and precancerous (CIN 2/3, AIS, CAH) and malignant (carcinoma) histologic outcomes alone were analyzed (refer to Table 2), CIN 2/3 was strongly related to hr AGC results in women younger than 40 years. All AIS patients were younger than 50 years. Six of 10 AIS cases (60%) were detected in women aged 40 to 49 years, and all 10 cases (100%) followed AGC results. Endometrial neoplasias (CAH and carcinomas) predominated in women 50 years and older. In total, 13 of 14 cervical glandular neoplasias cases (92.9%), 10 of 10 AIS cases (100%), and 3 of 4 cervical adenocarcinoma cases (75%) followed hr AGC results. The positive predictive value, negative predictive value, sensitivity, and specificity for reflex hrhpv DNA testing with AGC to detect cervical glandular neoplasia were 17.3%, 99.6%, 92.9%, and 79.0%, respectively. Arch Pathol Lab Med Vol 134, January 2010 HPV Testing in AGC Pap Zhao et al 105
4 Table 2. Age and Subsequent Significant Histologic Diagnoses in Women With Atypical Glandular Cell Papanicolaou Tests and High-Risk Human Papillomavirus (hrhpv) Test Results,40 y $40 y to,50 y $50 y Total Histologic Diagnoses (n = 41) HPV (n = 64) (n = 19) HPV 2 (n = 108) (n = 15) HPV (n = 62) (n = 75) HPV (n = 234) CIN 2/3 10 a (24.4) 1 (1.6) 2 b (10.5) 0 1 (6.7) 0 13 (17.3) 1 (0.4) Invasive cervical adenocarcinoma 2 (4.9) 0 1 (5.3) (1.6) 3 (4.0) 1 (0.4) AIS 4 a (9.8) 0 6 b (31.6) (13.3) Endometrial carcinoma (1.9) 0 6 (9.7) 0 8 (3.4) CAH (1.9) 0 3 (4.8) 0 5 (2.1) Metastatic carcinoma (0.9) (0.4) Total 13 (31.7) 1 (1.6) 8 (42.1) 5 (4.6) 1 (6.7) 10 (16.1) 22 (29.3) 16 (6.8) Abbreviations: AIS, adenocarcinoma in situ; CAH, complex atypical endometrial hyperplasia; CIN 2/3 indicates cervical intraepithelial neoplasia grades 2/3. a There were 3 cases with both AIS and CIN 2/3. b There was 1 case with both AIS and CIN 2/3 for a total of 4 cases with AIS and CIN 2/3, all. However, HPV 2 AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap test findings in this series, all in women 40 years or older, including endometrial adenocarcinomas (n 5 8), ovarian carcinoma (n 5 1), and cervical adenosquamous carcinoma (n 5 1) in a woman in her 50s. Benign Histopathologic Outcomes Benign histologic follow-up results of endometrial and endocervical polyps, endometritis, endocervical tubal metaplasia, and endocervical microglandular hyperplasia are summarized in Table 3. COMMENT This study from a large, integrated, academic health system supports accumulating data that adjunctive hrhpv testing has substantial clinical utility in women with AGC Pap test findings As noted in previous studies, the largest group of clinically significant (precancerous) lesions or malignant lesions detected after AGC Pap test results were noninvasive high-grade CIN, CIN 2/ 3 and/or AIS. 24,29,30,32,33 A positive HPV test result with an AGC Pap test result significantly increases the positive predictive value for high-grade CIN and AIS. Age, in our data set, was strongly associated with different patterns of histologic outcome. Of 20 diagnosed cases of high-grade cervical intraepithelial neoplasia (CIN 2/3, AIS), 19 cases (95%) were in women younger than 50 years. None of 10 cases of AIS were detected in women 50 years or older. All 3 carcinomas detected in women younger than 50 years with AGC results were cervical adenocarcinomas. The only cervical carcinoma detected in a woman 50 years or older was an adenosquamous cervical carcinoma with an HPV 2 AGC/ASC-H Pap test result. In particular, 10 of 13 carcinomas (77%) detected after AGC Pap test findings in this series were in women 40 years and older with HPV 2 AGC Pap test results. Several recent clinical trials have proposed the possibility of using HPV testing as a primary screening test in older women, with cytology reserved for women with positive HPV test results. 50,51 This approach would have yielded negative screening test results for 10 of 13 carcinomas (77%) detected with AGC Pap test results in this study, including 1 of 4 cervical carcinomas (25%). In the largest reported age-stratified series of cervical adenocarcinomas, 49 of 132 cervical adenocarcinomas (37.1%) in women 40 years and older and 39 of 78 cervical adenocarcinomas (50.0%) in women 50 years and older tested negative for HPV. 52 The absence of HPV has been significantly associated with high age at diagnosis for cervical adenocarcinoma. 53 It would be unfortunate if some of the complementary benefits of cytologic screening and adjunctive HPV cotesting were to be lost in proposed algorithms employing primary HPV screening Whether or not cytologic screening for endometrial adenocarcinoma is a realistic benefit of cytologic screening remains a matter of some debate In this study, the largest group of AGC-detected carcinomas were endometrial carcinomas, all detected in women 40 years and older. Atypical glandular cell Pap test results also detected 5 cases of precancerous complex atypical endometrial hyperplasia. Similar results have been reported, especially in studies of AGCs favored to be endometrial in origin 60,61 or of AGCs in postmenopausal women. 62 Several investigators have noted that precise discrimination as to the likely site of origin of AGCs is often uncertain, 1,63 precluding clinical algorithms based solely on cytologicsuspected site of origin. Our results are consistent with, Table 3. Significant Benign Histologic Diagnoses and High-Risk Human Papillomavirus (hrhpv) Results Reported in 212 Cases of Atypical Glandular Cells With Nonneoplastic Follow-up Histologic Diagnoses hr (n = 27), hrhpv (n = 185), Total (n = 212), Endometrial polyp 1 (3.7) 23 (12.4) 24 (11.3) Endometritis 0 2 (1.1) 2 (0.9) Endocervical polyp 1 (3.7) 7 (3.8) 8 (3.8) Endocervical tubal metaplasia 1 (3.7) 13 (7.0) 14 (6.6) Microglandular hyperplasia 1 (3.7) 6 (3.2) 7 (3.3) Benign, other 23 (85.2) 137 a (74.1) 160 a (75.5) a A total of 3 cases had 2 benign lesions. 106 Arch Pathol Lab Med Vol 134, January 2010 HPV Testing in AGC Pap Zhao et al
5 and support, the most recent 2006 consensus guidelines for the management of women with AGCs, not otherwise specified. 64 A hoped for, but as yet undocumented, benefit of HPV testing in screening for developing cervical glandular neoplasia would be detection of glandular neoplasias at earlier and more prognostically favorable stages. 6 As noted previously, the effect of screening to prevent endocervical adenocarcinoma has been far less than for squamous cancers in population studies. 3 7 For most women with HPV-associated endocervical carcinoma, 52,65 more widespread HPV cotesting could offer an additional test to potentially offset sampling, screening, or interpretive false-negative cytology results, 66 particularly in women younger than 50 years. The benefits of HPV testing in screening for glandular cervical neoplasia may also supplement reported benefits associated with liquidbased cytology and computer-assisted screening. 2,67 69 References 1. Simsir A, Hwang S, Cangiarella J, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and prediction of cell of origin. Cancer. 2003;99(6): Lee KR, Daragh TM, Joste NE, et al. Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol. 2002;117(1): Andrae B, Kermetli L, Sparen P, et al. Screening preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008; 100(9): The International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2006;120(4): Mitchell H, Hocking J, Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer. 2003;99(6): Kinney W, Sawaya G, Sung H, Kearney K, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cervical screening. Acta Cytol. 2003;47(2): Herbert A, Singh N, Smith JAE. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12 year study in Southampton and South-west Hampshire. Cytopathology. 2001;12(1): Schnatz PF, Guile M, O Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006;107(3): Haidopoulos DA, Stefanidis K, Rodolakis A, Pilalis A, Symiakaki I, Diakomanolis E. Histologic implications of Pap smears classified as atypical glandular cells. J Reprod Med. 2005;50(3): Chhieng DC, Cangiarella JF. Atypical glandular cells. Clin Lab Med. 2003; 23(3): Wood MD, Horst JA, Bibbo M. Weeding atypical glandular cell lookalikes from the true atypical lesions in liquid-based Pap tests: a review. Diagn Cytopathol. 2007;35(1): Chichareon SB, Tocharoenvanich S. Risk factors of having high-grade cervical intraepithelial neoplasia/invasive carcinoma in women with atypical glandular cells of undetermined significance smears. Int J Gynecol Cancer. 2006; 16(2): Gurbuz A, Karateke A, Kabaca C, Kir G. Atypical glandular cells: improvement in cytohistologic correlation by the 2001 Bethesda system. Int J Gynecol Cancer. 2005;15(5): Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105(3): Torres JC, Derchain SF, Gontijo RC. Atypical glandular cells: criteria to discriminate benign from neoplastic lesions and squamous from glandular neoplasia. Cytopathology. 2005;16(6): Barreth D, Faught W, Schepansky A, Johnson G. The relationship between atypical glandular cells of undetermined significance on Pap smear and a clinically significant histologic diagnosis. J Obstet Gynaecol Can. 2004;26(10): Chhieng DC, Gallaspy S, Yang H, Roberson J, Eltoum I. Women with atypical glandular cells: a long-term follow-up study in a high-risk population. Am J Clin Pathol. 2004;122(4): Scheiden R, Wagener C, Knolle U, Dippel W, Capesius C. Atypical glandular cells in conventional cervical smears: incidence and follow-up. BMC Cancer. 2004;4: Cangiarella JF, Chhieng DC. Atypical glandular cells an update. Diagn Cytopathol. 2003;29(5): Jeng CJ, Liang HS, Wang TY, Shen J, Yang YC, Tzeng CR. Cytologic and histologic review of atypical glandular cells (AGC) detected during cervical cytology screening. Int J Gynecol Cancer. 2003;13: Smith HO, Benwick M, Qualls CF, Verschraegen CF, Wiggins C. Thirtyyear trends in cervical cancer incidence rates: a surveillance, epidemiology, and end results program population-based study. In: Plenary Sessions Compendium of the Annual Meeting on Women s Cancer from the Society of Gynecologic Oncologists; March 4 7, 2007; San Diego, CA. Abstract Linder J, Keene J, Sheets E. Cervical cancer reduction through higher sensitivity Pap testing: observed vs. calculated effects. Cancer. 2007;111: Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128(11): Chen L, Yang B. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer. 2008; 114(4): Rabelo-Santos SH, Derchain SFM, do Amaral Westin MC, et al. Endocervical glandular cell abnormalities in conventional cervical smears: evaluation of the performance of cytomorphological criteria and HPV testing in predicating neoplasia. Cytopathology. 2008;19(1): Costa S, Negri G, Sideri M, et al. Human papillomavirus (HPV) test and Pap smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. Gynecol Oncol. 106(1): Diaz-Montes TP, Farinola MA, Zahurak ML, Bristow RE, Rosenthal DL. Clinical utility of atypical glandular cells (AGC) classification: cytohistologic comparison and relationship to HPV results. Gynecologic Oncol. 2007;104(2): Oliveira ER, Derchain SF, Sarian LO, et al. Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer. 2006;16(3): Saqi A, Gupta PK, Eroll M, et al. High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diagn Cytopathol. 2006;34(3): Fetterman B, Shaber R, Pawlick G, Kinney W. Human papillomavirus testing in routine clinical practice for prediction of underlying cervical intraepithelial neoplasia 2/3+ at initial evaluation and in follow-up of women with atypical glandular cell Papanicolaou tests. J Lower Gen Tract. 2006;10(3): Werner CL, Griffith WF, West AM, Ashfaq R. Reflex human papillomavirus DNA testing of atypical glandular cell cervical cytologies [abstract]. J Lower Gen Tract. 2006;10(3): Irvin W, Evans SR, Andersen W, et al. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol. 2005;193(2): Oliveira ER, Derchain SF, Rabelo-Santos SH, et al. Detection of high-risk human papillomavirus (HPV) DNA by hybrid capture II in women referred due to atypical glandular cells in the primary screening. Diagn Cytopathol. 2004;31(1): Krane JF, Lee KR, Sun D, Yuan L, Crum CP. Atypical glandular cells of undetermined significance: outcome predictions based on human papillomavirus testing. Am J Clin Pathol. 2004;121(1): Derchain SFM, Rabelo-Santos SH, Sarian LO, et al. Human papillomavirus detection and histologic findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol. 2004;95: Rowe LR, Aldeen W, Bentz JS. Prevalence and typing of HPV DNA by hybrid capture II in women with ASCUS, ASC-H, LSIL, and AGC on ThinPrep Pap tests. Diagn Cytopathol. 2004;30(6): Ronnett BM, Manos MM, Ramsley JE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol. 1999;30(7): Guidos R, Schiffman M, Solomon D, Burke L. Postcolposcopy management strategies for women referred with low grade squamous intraepithelial lesions or human papillomavirus-positive atypical squamous cells of undetermined significance: a two year prospective study. Am J Obstet Gynecol. 2003; 188(6): Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16): Reuss E, Price J, Koonings P. Atypical Glandular cells of undetermined significance: subtyping as a predictor of outcome. J Reprod Med. 2001;46(8): Simsir A, Hwang S, Cangiarella J, et al. Glandular cell atypia on Papanicolaou smears: interobserver variability in the diagnosis and predication of the cell of origin. Cancer. 2003;99(6): Barreth D, Faught W, Schepansky A, et al. The relationship between atypical glandular cells of undetermined significance on pap smear and a clinically significant histologic diagnosis. J Obstet Gynaecol Can. 2004;26(10): Arch Pathol Lab Med Vol 134, January 2010 HPV Testing in AGC Pap Zhao et al 107
6 43. DeSimone CP, Day ME, Towar MM, et al. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol. 2006;107(6): Holland-Barkis P, Forjuoh SN, Couchman GR, et al. Primary care physicians awareness and adherence to cervical cancer screening guidelines in Texas. Prev Med. 2006;42(2): Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI. Lack of adherence to practice guidelines for women with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105(3): Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetricians-gynecologists. Obstet Gynecol. 2003;102(2): US Census Bureau. American Community Survey (ACS) Web site. Accessed December 1, Dzura B, Quinn S, Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the cervix. Acta Cytol. 2006;50(3): Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003;41(9): Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7): Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3): Andersson S, Rylander E, Larson B, et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol Rep. 2003; 10(1): Andersson S, Larson B, Hjerpe A, et al. Adenocarcinoma of the uterine cervix: the presence of human papillomavirus and the method of detection. Acta Obstet Gynecol Scand. 2003;82(10): Ferenczy A. Cervical cancer screening: the blessing of molecular technology. HPV Today. 2008;15: Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2008;124(3): Wright T. Cervical Cancer Screening in the 21st Century: is it time to retire the Pap? Clin Gynecol Obstet. 2007;50(2): Kipp B, Medeiros F, Campion MB, et al. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study. Cancer. 2008; 114(4): Frable WJ. Screening for endometrial cancer? Cancer. 2008;114(4): Mitchell H, Giles G, Medley G. Accuracy and survival benefit of cytological prediction of endometrial carcinoma on routine cervical smears. Int J Gynecol Pathol. 1993;12(1): Saad RS, Takei H, Liu YL, Silverman JE, Lipscomb JT, Ruiz B. Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears. Acta Cytol. 2006;50(1): Chieng D, Elgert P, Cohen JM, Cangierella JF. Clinical significance of atypical glandular cells of undetermined significance, favor endometrial origin. Cancer. 2001;93(6): Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer. 2001;93: Reuss J, Price J, Koonings P. Atypical glandular cells of undetermined significance: subtyping as a poor predictor. J Reprod Med. 2001;46(8): Wright TC, Massad S, Dunton CJ, et al consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4): Castellsagué X, Díaz M, de Sanjosé S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98(5): Kalir T, Simsir A, Demopoulos HB, Demopoulos RI. Obstacles to early detection of endocervical adenocarcinoma. Int J Gynecol Pathol. 2005;24(4): Ashfaq R, Gibbons D, Vela C, Saboorian MH, Iliya F. Thin Prep Pap test: accuracy for glandular disease. Acta Cytol. 1999;43(1): Schorge JO, Hossein Saboorian M, Hynan L, Ashfaq R. Thin Prep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study. Cancer. 2002;96(6): Friedlander MA, Rudomina D, Lon O. Effectiveness of the Thin Prep imaging system on the detection of adenocarcinoma in the gynecologic system. Cancer. 2008;114(1): Arch Pathol Lab Med Vol 134, January 2010 HPV Testing in AGC Pap Zhao et al
Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationCervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix
DOI:10.31557/APJCP.2019.20.2.377 Cervical Screening Results Leading to Detecting Cervical AIS RESEARCH ARTICLE Editorial Process: Submission:09/27/2018 Acceptance:01/18/2019 Cervical Screening Results
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationCME/SAM. Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results
Anatomic Pathology / HPV-Negative ASC-H Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results David Cohen, MD, R. Marshall Austin, MD,
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationMaterials and Methods
Accuracy of Diagnosis of Atypical Glandular Cells Conventional and ThinPrep Reena Ramsaroop, M.B., Ch.B., F.F.Path., Ph.D.* and Ien Chu, N.Z.I.M.L.T., Q.T.A., Q.T.O. The incidence of glandular cervical
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationSignificance of High-Risk Human Papillomavirus DNA Detection in Women 50 Years and Older With Squamous Cell Papanicolaou Test Abnormalities
Significance of High-Risk Human Papillomavirus DNA Detection in Women 50 Years and Older With Squamous Cell Papanicolaou Test Abnormalities Chengquan Zhao, MD; Shuping Zhao, MD, PhD; Amer Heider, MD; R.
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationVery Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests
292 Very Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests Chengquan Zhao, MD 1 Esther Elishaev, MD 1 Ke-Hai Yuan, PhD 2 Jing Yu, MD 1 R. Marshall
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationEvaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationCervical cytology screening has led to a reduction in cancer mortality
CANCER CYTOPATHOLOGY 105 ThinPrep Pap Test Performance and Biopsy Follow-Up in a University Hospital A. Betts Carpenter, M.D., Ph.D. Diane D. Davey, M.D. Department of Pathology and Laboratory Medicine,
More informationIJC International Journal of Cancer
IJC International Journal of Cancer High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis Freija Verdoodt 1, Xuezhi Jiang 2,3, Mark Williams 2, Peter
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationGlandular lesions in cervical cytology. Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia
Glandular lesions in cervical cytology Margareta Strojan Fležar Institute of Pathology Faculty of Medicine University of Ljubljana Slovenia 2nd PANNONIA CONGRESS OF PATHOLOGY, SIÓFOK, HUNGARY, 17-19 MAY
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Comparison of Performance of Conventional and ThinPrep Gynecologic Preparations in the College of American Pathologists Gynecologic Cytology Program Andrew A. Renshaw,
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationGYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationHKCOG GUIDELINES NUMBER 3 (revised November 2002) published by The Hong Kong College of Obstetricians and Gynaecologists
HKCOG Guidelines Guidelines on the Management of An Abnormal Cervical Smear Number 3 revised November 2002 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College of
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationColposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationReporting Endometrial Cells in Women 40 Years and Older Assessing the Clinical Usefulness of Bethesda 2001
Anatomic Pathology / THE EFFECT OF BETHESDA 2001 ON REPORTING OF ENDOMETRIAL CELLS Reporting Endometrial Cells in Women 40 Years and Older Assessing the Clinical Usefulness of Bethesda 2001 Aylin Simsir,
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationCervical Cancer Prevention in the 21 st Century Changing Paradigms
Cervical Cancer Prevention in the 21 st Century Changing Paradigms Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M.
More informationThe prevalence and spectrum of atypical glandular cells in Dubai hospital: A local experience
DOI: 10.15415/jmrh.2016.31006 The prevalence and spectrum of atypical glandular cells in Dubai hospital: A local experience RAVIRANI SAMUEL 1, MANAL M.M. ABDULRAZZAQ 1, BADR ABDULLGAFFAR 2, HASSAN Y. HOTAIT
More informationAn audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia
DOI:10.1111/j.1365-2303.2009.00695.x An audit of liquid-based cervical cytology screening samples (ThinPrep and SurePath) reported as glandular neoplasia S. A. Thiryayi, J. Marshall and D. N. Rana Manchester
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationName of Policy: Speculoscopy
Name of Policy: Speculoscopy Policy #: 095 Latest Review Date: September 2011 Category: Medicine/OB Gyn Policy Grade: C Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationHow invasive cervical cancer audit affects clinical practice
How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust How invasive
More informationEU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
More informationGLANDULAR LESIONS PITFALLS IN MANAGEMENT. Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016
GLANDULAR LESIONS PITFALLS IN MANAGEMENT Dr Li Wai Hon HKSCCP The 15 th Anniversary Symposium 10 December 2016 Introduction Cervical glandular lesions are much less common than squamous lesion Incidence
More informationHigh-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics, and Clinical Meaning for Cervical Cancer
103 Ivyspring International Publisher Research Paper International Journal of Medical Sciences 2012; 9(1):103-107 High-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics,
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationOver-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
More informationINTRODUCTION HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY
HSIL AND CERVICAL CARCINOMA IN ASCUS CERVICAL CYTOLOGY PREVALENCE OF HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (HSIL) AND INVASIVE CERVICAL CANCER IN PATIENTS WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationAGC Subclasses and Risk of Invasive Cancers
AGC Subclasses and Risk of Invasive Cancers Xuezhi (Daniel) Jiang, MD, PhD Associate Professor of Obstetrics & Gynecology The Reading Hospital of Tower Health Thomas Jefferson University Reading, PA Disclosures
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationCan LBC Completely Replace Conventional Pap Smear in Developing Countries
The Journal of Obstetrics and Gynecology of India (January February 2019) 69(1):69 76 https://doi.org/10.1007/s13224-018-1-7 ORIGINAL ARTICLE Can LBC Completely Replace Conventional Pap Smear in Developing
More informationEffectiveness of the ThinPrep Imaging System:
Effectiveness of the ThinPrep Imaging System: Clinical Experience in a Low Risk Screening Population Jacalyn L. Papillo, B.S., C.T., A.S.C.P., 1 * Timothy L. St. John, B.S., C.T., A.S.C.P., 1 and Gladwyn
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationSince the publication of the 2001 consensus
Reviews Oncology www.ajog.org 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests Thomas C. Wright Jr, MD; L. Stewart Massad, MD; Charles J. Dunton, MD;
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationComparison of Diagnostic Cytomorphology of Atypical Squamous Cells in Liquid-Based Preparations and Conventional Smears
The Korean Journal of Pathology 2012; 46: 365-369 ORIGINAL ARTICLE Comparison of Diagnostic Cytomorphology of Atypical Squamous Cells in Liquid-Based Preparations and Conventional Smears Jung Dal Lee 1,2
More informationThe LAST Guidelines in Clinical Practice. Implementing Recommendations for p16 Use
AJCP / Original Article The LAST Guidelines in Clinical Practice Implementing Recommendations for p16 Use Lani K. Clinton, MD, PhD, 1,2 Kyle Miyazaki, 1 Asia Ayabe, 1 James Davis, PhD, 2 Pamela Tauchi-Nishi,
More informationCervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens
Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens 3 Christine Bergeron, MD, PhD Introduction Carcinoma of the cervix is a slow growing cancer, which is preceded by precancerous
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationDetecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
More informationChapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
More informationPOST-CONIZATION FOLLOW-UP OF PATIENTS WITH HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION TREATED BY LEEP PROCEDURE: A LITERATURE REVIEW
POST-CONIZATION FOLLOW-UP OF PATIENTS WITH HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION TREATED BY LEEP PROCEDURE: A LITERATURE REVIEW Boureima Ali Nafissatou and Dong zhao * Department of Gynecology, Shanghai
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationUtility of Pap Smear in Cervical Screening in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 1 (2017) pp. 319-323 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2017.601.039
More informationInstructions For Use
MAN-02624-001 Rev. 004 page 1 of 15 Instructions For Use INTENDED USE The ThinPrep 2000 System is intended as a replacement for the conventional method of Pap smear preparation for use in screening for
More informationManagement Algorithms for Abnormal Cervical Cytology and Colposcopy
Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent
More informationWorkshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
More informationHPV Testing ASC-US. Jodie Zeke, a nurse practitioner, received initial CE2. 5. By Kim K. Choma, MSN, APN,C
CE2. 5 HOURS Continuing Education By Kim K. Choma, MSN, APN,C & ASC-US HPV Testing When the Pap result is atypical squamous cells of undetermined significance, testing for the human papillomavirus may
More informationOriginal Articles. Squamous Cell Carcinoma of the Cervix. A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice
Original Articles Squamous Cell Carcinoma of the Cervix A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice Ross A. Miller, MD; Lindsay L. Waters, MD; Dina R. Mody, MD; Kimberlee
More informationCase 3 - GYN. History: 66 year old, routine Pap test. Dr. Stelow
Case 3 - GYN History: 66 year old, routine Pap test Dr. Stelow Case 3 66 year year old woman Routine Pap Test Cytologic Features 3 dimensional clusters of cells with small to moderate amount of
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationMINI-REVIEW. Histopathological Outcomes of Women with Abnormal Cervical Cytology: a Review of Literature in Thailand
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.16.6489 Histopathological Outcomes of Women with Abnormal Cervical Cytology: A Review of Literature in Thailand MINI-REVIEW Histopathological Outcomes of Women
More informationGUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
More information